AU2001255696A1 - Telomerase inhibitors and methods of their use - Google Patents

Telomerase inhibitors and methods of their use

Info

Publication number
AU2001255696A1
AU2001255696A1 AU2001255696A AU5569601A AU2001255696A1 AU 2001255696 A1 AU2001255696 A1 AU 2001255696A1 AU 2001255696 A AU2001255696 A AU 2001255696A AU 5569601 A AU5569601 A AU 5569601A AU 2001255696 A1 AU2001255696 A1 AU 2001255696A1
Authority
AU
Australia
Prior art keywords
methods
telomerase inhibitors
telomerase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001255696A
Inventor
Allison C. Chin
Sergei Gryaznov
Tracy Matray
Richard L. Tolman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of AU2001255696A1 publication Critical patent/AU2001255696A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
AU2001255696A 2000-04-27 2001-04-26 Telomerase inhibitors and methods of their use Abandoned AU2001255696A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20017100P 2000-04-27 2000-04-27
US60200171 2000-04-27
PCT/US2001/013419 WO2001080855A1 (en) 2000-04-27 2001-04-26 Telomerase inhibitors and methods of their use

Publications (1)

Publication Number Publication Date
AU2001255696A1 true AU2001255696A1 (en) 2001-11-07

Family

ID=22740625

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001255696A Abandoned AU2001255696A1 (en) 2000-04-27 2001-04-26 Telomerase inhibitors and methods of their use

Country Status (2)

Country Link
AU (1) AU2001255696A1 (en)
WO (1) WO2001080855A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020160983A1 (en) * 2001-03-16 2002-10-31 Alberto Bargiotti Substituted benzopyranones as telomerase inhibitors
ATE361746T1 (en) * 2002-03-06 2007-06-15 Medical Res And Education Trus BOTANICAL EXTRACT WITH ANTI-CANCER ACTIVITY CONTAINING ISOLIQUIRITIGENIN
EP1803809A3 (en) * 2005-08-12 2007-12-19 Abgenomics Corporation Modulation of peroxisome proliferator-activated receptors
KR100973495B1 (en) * 2007-12-11 2010-08-03 재단법인서울대학교산학협력재단 Anticancer agent containing 5-deoxykaempferol
KR100930905B1 (en) * 2007-12-11 2009-12-10 재단법인서울대학교산학협력재단 Composition for the prevention or treatment of diseases related to the imbalance of inhibition and homeostasis of intercellular information transmission through gap binding, including 5-deoxycamphorol
WO2011029956A1 (en) * 2009-09-14 2011-03-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Flavones and flavanones derivates as dna methyltransferases inhibitors
CN102869255B (en) 2010-02-12 2016-08-31 内瓦利斯治疗公司 The novel inhibitors of GSNO reductase
JP5639665B2 (en) 2010-02-12 2014-12-10 エヌサーティー・ファーマシューティカルズ・インコーポレーテッド Chromone inhibitor of S-nitrosoglutathione reductase
US20150291547A1 (en) * 2011-09-26 2015-10-15 Nanyang Polytechnic Small molecules for extending the well being of cells and methods of use thereof
US10806716B2 (en) 2016-02-04 2020-10-20 Auransa Inc. Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
WO2023078252A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04103529A (en) * 1990-08-24 1992-04-06 Tatsuo Miyoshi Carcinostatic agent
DE4407484A1 (en) * 1993-12-03 1995-06-08 Werner Prof Dr Kreutz Cancer medicament for parenteral admin.

Also Published As

Publication number Publication date
WO2001080855A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
AU6340600A (en) Telomerase inhibitors and methods of their use
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2001241474A1 (en) Biosensor compositions and methods of use
AU2002314466A1 (en) Withasol and methods of use
AU2002211389A1 (en) Microfluidic devices and methods of use
AU2002320058A1 (en) Magnetic-nanoparticle conjugates and methods of use
AU2002323210A1 (en) Bio-synthetic photostimulators and methods of use
AU2001285020A1 (en) P97-active agent conjugates and their methods of use
AU2001234437A1 (en) Deicing compositions and methods of use
EP1448218A4 (en) Beta-secretase inhibitors and methods of use
AU2001270260A1 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
AU1334602A (en) Osteopontin-coated surfaces and methods of use
AU2002337913A1 (en) Glycosulfopeptide inhibitors and methods of use thereof
AU2001255696A1 (en) Telomerase inhibitors and methods of their use
PL361733A1 (en) Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
AU2001293048A1 (en) Antiviral compositions and methods of use
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU2002303712A1 (en) Novel telomerase inhibitors and uses therefor
HUP0204376A3 (en) Novel invertase inhibitors and methods of use
AU2002310237A1 (en) Sponge-derived terpenoids and methods of use
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2002306845A1 (en) Telomerase inhibitors and methods of their use
EP1263935A4 (en) Scytonemin and methods of using thereof